The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
Authors
Keywords
-
Journal
DRUGS
Volume 78, Issue 7, Pages 717-726
Publisher
Springer Nature
Online
2018-04-16
DOI
10.1007/s40265-018-0901-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
- (2017) Xiaoxin X. Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS
- (2017) Volker Vallon et al. Nature Reviews Nephrology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
- (2017) Paresh Dandona et al. Lancet Diabetes & Endocrinology
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
- (2016) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- (2016) Volker Vallon et al. DIABETOLOGIA
- Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
- (2016) Panai Song et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
- (2015) Arthur T. Sands et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
- (2015) Wataru Ogawa et al. Journal of Diabetes Investigation
- Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association
- (2014) Sarah D. de Ferranti et al. DIABETES CARE
- Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
- (2014) Kamlesh Khunti et al. DIABETES CARE
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
- (2014) Masanori Yokono et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
- (2014) T. D. Pessoa et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
- (2011) Scott C. Thomson et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney
- (2011) Volker Vallon et al. Annual Review of Physiology
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- The clinical significance of hyperfiltration in diabetes
- (2010) G. Jerums et al. DIABETOLOGIA
- Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis
- (2009) G. M. Magee et al. DIABETOLOGIA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now